Nudges via email to increase GDMT in diabetic CKD
Is tacrolimus superior to MMF in pediatric steroid sensitive nephrotic syndrome?
Ensayo STAMP: ¿Tacrolimus o Micofenolato en el síndrome nefrótico pediátrico?
El síndrome nefrótico en niños puede implicar recaídas frecuentes, alta carga de esteroides y decisiones terapéuticas difíciles. Entonces, ¿cuál mantiene mejor la remisión: tacrolimus o micofenolato de mofetilo?
Revisa el VA y únete a la discusión en #NephJC
The STAMP Trial VA: Who Gets the Approval—TAC or MMF in Pediatric Nephrotic Syndrome?
Nephrotic syndrome in kids can mean frequent relapses, high steroid burden, and tough treatment choices. So which helps maintain remission better: Tacrolimus or MMF?
See the Visual Abstract Krithika Mohan
TAC or MMF—what works better in pediatric nephrotic syndrome?
Nephrotic syndrome in children, especially those with frequent relapses or steroid dependence, remains a therapeutic challenge. The STAMP trial compared tacrolimus and mycophenolate mofetil to help guide treatment decisions.
STAMP of Approval: Tacrolimus vs MMF in Pediatric Nephrotic Syndrome
Does desmopressin help with post kidney biopsy bleeding?
Check out this thread, summarizing discussions on two studies.
Advance-HTN: Return of the systolic order – Lorundrostat’s role in restoring balance
Does Lorundrostat Effectively Lower Blood Pressure in Uncontrolled Hypertension?
Stunning visual abstract summarizing NEJM study, by Priti Meena
Does your heart skip a beat with chronic hyperkalemia in dialysis?
ADAPT trial: fixing the K+ numbers, while hoping to translate them into outcomes
Is a lower BP the road to better outcomes in diabetes?
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
Double Trouble: ddAVP and the Bleeding Biopsy
REGENCY: A B-Cell Super Destroyer in Lupus
Pain Coping Skills Training in Diaysis
Can we train to deal with the pain? HOPE trial shows us that non-pharmacological intervention can be an option. Visual abstract by Cristina Popa
HOPE-ing and Coping with Pain in Dialysis
BPROAD: Sprinting down the BP Road in Diabetes
Potassium Rollercoaster Heartbreak
FLOZINATing to the Future- Long Term Effects of Empagliflozin in Patients with CKD
Playing It Safe: Can Felzartamab Fill the Gap in AMR Treatment?
The pressure is on! Unravelling the ESPRIT of Intensive vs Standard BP Control
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.